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Dear Editor,
In a recent article published in the European Journal of Vascular
andEndovascular Surgery,Hellentahlet al. provided furtherevidence
that plasma biomarkers, such as matrix metalloproteinase-9 (MMP-
9), may be a valuable adjunctive diagnostic tool for predicting the
presence of an endoleak post endovascular aneurysmrepair (EVAR).1
Although EVAR compares favourably to open surgical abdom-
inal aortic aneurysm (AAA) repair in terms of short term mortality
and morbidity, the potential longer term complications mandate
the lifelong follow up post procedure. The cost involved with the
surveillance program, and the inconvenience for the patients to
partake in a lifelong surveillance, remain a signiﬁcant issue.2 There-
fore, the discovery of potential diagnostic plasma biomarker(s) for
the purpose of endoleak detectionwould represent a breakthrough
in current standard clinical practice; it would also underpin the
ethos of surgical translational research.
In our search for potential plasma biomarkers for clinical appli-
cations, it is critical to examine the pre-analytical factors which
may affect quantitative measurements of the biomarkers. MMP-9
is known to be affected by several pre-analytical issues, including
the kind of sample matrix collected or the type of anti-coagulants
used for the preparation of plasma. Blood components such aswhite
blood cells and platelets are sources of MMP-9 and may release
MMP-9 ex-vivo during the coagulation process. It has been shown
that serum levels ofMMP-9 are higher than thatmeasured in paired
plasma, and that higher levels of MMP-9 are measured in EDTA
plasma compared to paired lithium heparin plasma.3,4
Given the pre-analytical inﬂuence on themeasuredMMP-9 levels,
itwouldbeworthwhile for researchpublications, suchas the reportby
Hellentahl et al., to include the sample preparation protocol as part of
themethods section. Thiswill allow for comparisons between studies,
and to guide potential clinical applications in the future.Acknowledgement
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Re: Utility of Plasma Matrix Metalloproteinase-9 as a Possible
Diagnostic Marker of Endoleak Post Endovascular Aneurysm
Repair
Dear Sir,
We would like to thank Lee and Handa for their interest in and
commentary on our report. We share their views on the inﬂuence
of pre-analytical processing on the measured MMP-9 levels. More-
over, we support the necessity of inclusion of the sample prepara-
tion protocol for comparisons between studies. However, since the
nature of this article was a short report, we were unable to report
details of the materials and methods. We therefore gladly provide
the details on the pre-analytical processing of our samples and
assay protocol in the present reply.
Blood Collection
Venous blood was drawn via an antecubital vein puncture and
collected inEDTAbuffered (K2E7.2mg) vacutainer for plasma. ExactlyDOI of original article: 10.1016/j.ejvs.2012.01.033.
Correspondence / European Journal of Vascular and Endovascular Surgery 43 (2012) 610–613 61130minaftercollection, bloodwascentrifuged (15min,3000g,4 C)and
multiple aliquots were stored at exactly 1 h after collection at 80 C
pendinganalysis.Asdemonstratedbyothers, concentrationandactivity
of MMP is stable during long term storage at80 C.1
Assays
Plasma levels of MMP- 2, -9 and TIMP-1 were determined
by means of a commercially available enzyme linked immunosor-
bent assay (GE Healthcare/lifesciences, Upssala, Sweden) according
to themanufacturer’s guidelines and were determined in duplicate.
Duplicates with less than 10% within assay variation in concentra-
tion were accepted and means were determined for further anal-
ysis. The between-assay variation (7% for MMP-2, 10% for both
MMP-9 and TIMP-1) was determined by the manufacturer.Yours faithfully,Reference
1 Sulik, A., Wojtkowska, M. & Oldak, E. 2008. Preanalytical factors affecting the
stability of matrix metalloproteinase-2 concentrations in cerebrospinal ﬂuid.
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doi:10.1016/j.ejvs.2012.02.001Factors Affecting Amputation-free Survival Rates in Critical
Limb IschemiaDOI of original article: 10.1016/j.ejvs.2012.01.034.First of all, we would like to congratulate the authors upon their
study investigating the factors affecting amputation-free survival in
the patients with critical limb ischemia (CLI).1 Cilostazol is not
mentioned among the medical treatment protocols provided to the
patients in the article, whereas there are a number of studies report-
ing lower amputation rates upon cilostazol administration in the
patients with CLI who had undergone endovascular intervention.2,3
Moreover, cilostazol administration was also documented to pull
down the amputation rates even in the cases with CLI in whom no
intervention was undertaken.4,5 Therefore, we believe the
amputation-free survival rates emerging in the present study would
be more accurate if an evaluation is made by taking into consider-
ation that cilostazol is not used in the study. Likewise, we also noted
in the study that extra-anatomic by-pass (EAB) procedure is imple-
mented in 3 out of 15 patients undergoing revascularization due to
ischemic pain. If EAB was undertaken in these patients during the
ﬁrst surgical intervention, what was the actual reason behind? If
EAB procedurewas preferred in these patients owing to the presence
of previous surgical operation, do you think the previous history ofvascular surgery had an impact on the amputation rates?We believe
that evaluation of the present study would be comprehended much
more thoroughly by keeping all the aforementioned issues in mind.
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doi:10.1016/j.ejvs.2012.01.034Response to Letter to the Editor: Factors Affecting Amputation-
Free Survival Rates in Critical Limb IschemiaWe appreciate the comments concerning our article on
amputation-free survival in patients with CLI.
We collected our data in 2004 and 2005. At that time, cilostazol
was not yet approved for treatment of patients with PAD, in
Germany. Therefore, we do not have any data concerning the inﬂu-
ence of cilostazol on amputation-free survival in our study popula-
tion. Nevertheless, we agree with the authors that cilostazol mighth-
a-
ve
